-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Benzinga·08/05/2026 13:24:21
Listen to the news
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.